ZLY28 is a novel, first-in-class compound with specific intestinal restriction and oral activity, serving as a dual modulator of FXR and FABP1. Additionally, it is a pioneering anti-NASH agent, utilized in the study of nonalcoholic steatohepatitis (NASH)
Molecular Weight:
520.4
Formula:
C29H23Cl2NO4
Target:
FXR
* VAT and and shipping costs not included. Errors and price changes excepted
